The YODA Project
Research Proposal Due Diligence Assessment

Part 1: General Information	
YODA Project (Protocol) ID:	2017-1746
Date:	12 Jul 2017-updated 4 Dec 2019
Product Name:	Galantamine/Risperidone/Topiramate/Ustekinumab/ Infliximab/ Golimumab/ Canagliflozin
Therapeutic Area:	Neuroscience/Immunology/ Metabolism
Product Class:	Acetylcholinesterase inhibitor/ atypical antipsychotics/ antiepileptic (AED) agent/ mAB anti-IL12 / anti-IL23/ Tumor necrosis factor (TNF) blocker/ SGLT-2 inhibitor/
Condition(s) Studied:	Alzheimer's, Dementia, Migraine, Psoriasis, Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis/ Type 2 Diabetes
Protocol Number(s) and Title(s):	**Galantamine/Risperidone/Topiramate:** NCT00216593 GAL-ALZ-302 NCT00236574 GAL-INT-11 NCT00236431 GAL-INT-18 NCT00034762 RIS-USA-232 NCT00210912 CAPSS-276 NCT00212810 CAPSS-381 NCT00236509 TOPMAT-MIGR-001 NCT00231595 TOPMAT-MIGR-002 NCT00236561 TOPMAT-MIGR-003 **Ustekinumab:** NCT00267969 C0743T08 NCT00307437 C0743T09 NCT01369329 CNTO1275CRD3001 NCT01369342 CNTO1275CRD3002 NCT01369355 CNTO1275CRD3003 NCT01009086 CNTO1275PSA3001 NCT01077362 CNTO1275PSA3002 **Golimumab:** NCT00264537 C0524T05 NCT00264550 C0524T06 NCT00265096 C0524T08 NCT00265083 C0524T09 NCT00299546 C0524T11 NCT00361335 C0524T12 NCT00487539 C0524T17 NCT00488631 C0524T18 NCT00973479 CNTO148ART3001 **Infliximab:** NCT00207662 C0168T21 NCT00207766 C0168T26 NCT00236028 C0168T29 NCT00036439 C0168T37 NCT00096655 C0168T46 NCT00094458 C0168T67 **Canagliflozin:**

The YODA Project
Research Proposal Due Diligence Assessment

	NCT01106625 28431754DIA3002 NCT01081834 28431754DIA3005 NCT01106677 28431754DIA3006 NCT00968812 28431754DIA3009 NCT01106651 28431754DIA3010 NCT01106690 28431754DIA3012 NCT01137812 28431754DIA3015 NCT01989754 28431754DIA4003 NCT01809327 28431754DIA3011 NCT01381900 28431754DIA3014 NCT01032629 28431754DIA3008 NCT00642278 28431754DIA2001

Part 2: Data Availability

Question:	Response:
Data Holder has authority to provide clinical trial data or development partner has agreed to share clinical trial data.	Yes
Comments: N/A	
Data Holder has shareable electronic clinical trial data or data can be converted to electronic format.	Yes
Comments: N/A	
De-identification and redaction of clinical trial data in accordance with current HIPAA and EU criteria allows protection of participant privacy and confidentiality.	Yes
Comments: N/A	
The product and relevant indication studied has either been approved by regulators in the US and EU, or terminated from development.	Yes
Comments: N/A	
Data Holder has completed the clinical trial and trial has been completed for a period of at least 18 months (or results published in peer-reviewed biomedical literature).	Yes
Comments: N/A	

Part 3: Data Availability Summary

Based on the responses to the above Data Availability questions, the requested clinical trial data can be made available for data sharing.	Yes

Part 4: Proposal Review

Question:	Response:
Summary-level CSR data is appropriate for the proposed analysis.	No
Participant-level data is appropriate for the proposed analysis.	Yes
A similar analysis is underway or completed/pending disclosure by Janssen.	No
Comments:	